Skip to main content
Clinical Trials/EUCTR2017-001253-13-BE
EUCTR2017-001253-13-BE
Active, not recruiting
Phase 1

Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? - ROCHIMS (Role of Cerebral Hypoperfusion In Multiple Sclerosis)

Z Brussel0 sites30 target enrollmentJuly 11, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Z Brussel
Enrollment
30
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 11, 2017
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Z Brussel

Eligibility Criteria

Inclusion Criteria

  • \- Patients with the diagnosis of relapsing\-remitting MS, according to the 2010 Revised Mc Donald Criteria
  • \- Age \> 18 years
  • \- Written informed consent must be obtained
  • \- EDSS score \< or equal to 4
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 25
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 5

Exclusion Criteria

  • \- Clinical evidence of MS relapse within 3 months prior to inclusion.
  • \- Known contra\-indications for bosentan: liver dysfunction (AST and/or ALT \> 3 x ULN), use of cyclosporine A and glibenclamide, allergy
  • \- Pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials